Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Mentice

14.80 SEK

0.00 %

Less than 1K followers

MNTC

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
0.00 %
+27.59 %
+8.42 %
-27.96 %
-41.24 %
-40.78 %
-58.38 %
-82.35 %
-77.83 %

Mentice operates in the medical technology sector. The company develops medical instruments for endovascular simulation and for training sessions in surgery. The programs are developed for use in educational purposes among hospitals and institutes. The largest operations are found in North America and Europe. In addition to the main business, opportunities for leasing, support, and technical service are offered. The headquarters are located in Gothenburg.

Read more
Market cap
416.26M SEK
Turnover
4.39K SEK
Revenue
290.33M
EBIT %
-4.27 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

7/5
2026

Interim report Q1'26

26/5
2026

General meeting '26

All
Press releases
3rd party
ShowingAll content types
Press release11/7/2025, 6:32 AM

DNB Carnegie Access: Mentice: Starting to show strong operating leverage – Q3 review

Mentice
Press release11/6/2025, 7:45 AM

DNB Carnegie Access: Mentice: Shows strong operational leverage – Q3 initial take

Mentice
Regulatory press release11/6/2025, 6:00 AM

Mentice publicerar bolagets delårsrapport för perioden juli – september 2025

Mentice

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/6/2025, 6:00 AM

Mentice publishes the company’s interim report for the period July – September 2025

Mentice
Regulatory press release10/23/2025, 1:30 PM

Nomination Committee has been appointed for Mentice AB (publ) Annual General Meeting 2026

Mentice
Regulatory press release10/23/2025, 1:30 PM

Valberedningen inför Mentice AB (publ) årsstämma 2026 är utsedd

Mentice
Press release10/23/2025, 7:00 AM

Mentice to Present Q3 2025 Interim Report via Webcast

Mentice
Press release10/3/2025, 6:53 AM

DNB Carnegie Access: Mentice: Cost-control focus – Q3 preview

Mentice
Press release8/21/2025, 6:15 AM

Mentice tillförs cirka 31,95 MSEK genom övertecknad företrädesemission

Mentice
Press release8/21/2025, 6:15 AM

Mentice receives approximately SEK 31.95 million through oversubscribed rights issue

Mentice
Press release8/4/2025, 1:00 PM

Mentice offentliggör informationsdokument avseende företrädesemission

Mentice
Press release8/4/2025, 1:00 PM

Mentice publishes information document regarding rights issue

Mentice
Press release8/1/2025, 11:00 AM

Mentice har erhållit ytterligare teckningsförbindelse motsvarande 3,4 MSEK i den pågående företrädesemissionen

Mentice
Press release8/1/2025, 11:00 AM

Mentice receives an additional Subscription Commitment of 3.4 MSEK in the upcoming Rights Issue

Mentice
Press release7/25/2025, 7:53 AM

DNB Carnegie Access: Mentice: Shows resilience in adj. EBITDA – Q2 review

Mentice
Press release7/24/2025, 11:05 AM

DNB Carnegie Access: Mentice: Recording from earnings call Q2 (25)

Mentice
Press release7/24/2025, 7:07 AM

DNB Carnegie Access: Mentice: FX and comparables tougher than feared – Q2 initial take

Mentice
Regulatory press release7/24/2025, 6:00 AM

Mentice genomför en företrädesemission om cirka 31,95 MSEK

Mentice
Regulatory press release7/24/2025, 6:00 AM

Mentice resolves on a rights issue of approximately SEK 31.95 million

Mentice
Regulatory press release7/24/2025, 5:00 AM

Mentice publicerar bolagets delårsrapport för perioden april–juni 2025

Mentice
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.